GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LadRx Corp (OTCPK:LADX) » Definitions » Shiller PE Ratio

LadRx (LADX) Shiller PE Ratio : (As of Apr. 26, 2024)


View and export this data going back to 1986. Start your Free Trial

What is LadRx Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


LadRx Shiller PE Ratio Historical Data

The historical data trend for LadRx's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LadRx Shiller PE Ratio Chart

LadRx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

LadRx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of LadRx's Shiller PE Ratio

For the Biotechnology subindustry, LadRx's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LadRx's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LadRx's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where LadRx's Shiller PE Ratio falls into.



LadRx Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

LadRx's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, LadRx's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.91/129.4194*129.4194
=-1.910

Current CPI (Dec. 2023) = 129.4194.

LadRx Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 48.000 99.695 62.312
201406 -168.000 100.560 -216.215
201409 -60.000 100.428 -77.321
201412 -144.000 99.070 -188.114
201503 -186.000 99.621 -241.636
201506 -126.000 100.684 -161.961
201509 -66.000 100.392 -85.084
201512 -210.001 99.792 -272.347
201603 -114.000 100.470 -146.847
201606 -162.000 101.688 -206.179
201609 -80.000 101.861 -101.644
201612 -33.000 101.863 -41.927
201703 -60.000 102.862 -75.491
201706 -60.000 103.349 -75.135
201709 -19.000 104.136 -23.613
201712 -13.000 104.011 -16.176
201803 -15.000 105.290 -18.438
201806 -10.000 106.317 -12.173
201809 -10.000 106.507 -12.151
201812 -7.000 105.998 -8.547
201903 -4.000 107.251 -4.827
201906 -4.000 108.070 -4.790
201909 -4.000 108.329 -4.779
201912 -9.000 108.420 -10.743
202003 -3.000 108.902 -3.565
202006 -4.000 108.767 -4.759
202009 -8.000 109.815 -9.428
202012 -3.000 109.897 -3.533
202103 -4.000 111.754 -4.632
202106 -3.000 114.631 -3.387
202109 -4.000 115.734 -4.473
202112 -24.000 117.630 -26.405
202203 -4.000 121.301 -4.268
202206 -2.250 125.017 -2.329
202209 -2.780 125.227 -2.873
202212 8.650 125.222 8.940
202303 -3.000 127.348 -3.049
202306 6.450 128.729 6.485
202309 -1.650 129.860 -1.644
202312 -1.910 129.419 -1.910

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


LadRx  (OTCPK:LADX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


LadRx Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of LadRx's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


LadRx (LADX) Business Description

Traded in Other Exchanges
N/A
Address
11726 San Vicente Boulevard, Suite 650, Los Angeles, CA, USA, 90049
LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.
Executives
Cary J Claiborne director 3056 SENECA CHIEF TRAIL, ELLICOTT CITY MD 21042
Stephen Snowdy officer: Chief Executive Officer C/O CYTRX CORPORATION, 11726 SAN VICENTE BOULEVARD, SUITE 650, LOS ANGELES CA 90049
Jennifer K. Simpson director C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019
Eric Curtis officer: Pres., Chief Operating Officer ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Felix Kratz officer: Vice President Drug Discovery 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Joel K Caldwell director 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Chawla Shanta M.d. officer: Senior VP-Drug Development 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Earl W Brien director 11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Olivia C Ware officer: Chief Commercial Officer 11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Cheryl Cohen director C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Eric Jay Selter director 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Anita J Chawla director 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Joseph Rubinfeld director C/O SUPERGEN INC, 4140 DUBLIN BLVD STE 200, DUBLIN CA 94568
Douglas Scott Wieland officer: Sr VP - Drug Development 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Louis Ignarro director 11726 SAN VICENTE BLVD, STE 650, LOS ANGELES CA 90049